---
title: "Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Transform-HTN"
description: "Formulary evidence on Lorundrostat (MLS-101, MT-4129) in Hypertension, in combination with other antihypertensive drugs: Transform-HTN. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 50 evidence topics quoted from 14 sources."
canonical: "https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence/transform-htn"
published: "2026-11-18T10:43:00-05:00"
modified: "2026-11-18T10:43:00-05:00"
---

# Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Transform-HTN

<a id="heading-3.1.3"></a>

## 3.1.3 Transform-HTN

<a id="heading-3.1.3.1"></a>

### 3.1.3.1 Objective

<a id="topic-3.1.3.1-1"></a>

#### Purpose stated in the ClinicalTrials.gov record

> “This study is to evaluate the long-term safety, efficacy and tolerability of lorundrostat (an aldosterone synthase inhibitor) in subjects with hypertension”
> “An Open-Label Extension Study to Assess the Long-Term Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension”

Source: [ClinicalTrials.gov NCT05968430](https://clinicaltrials.gov/study/NCT05968430)

<a id="topic-3.1.3.1-2"></a>

#### Purpose stated by the sponsor

> “Transform-HTN (NCT05968430) is a global open-label extension trial designed to assess the safety, efficacy and tolerability of lorundrostat in participants with hypertension, and includes participants who completed one of three eligible parent studies (Advance-HTN, Launch-HTN or Explore-CKD).”

Source: [Mineralys Therapeutics press release, Transform-HTN results (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/129/mineralys-therapeutics-presents-new-late-breaking-data-from)

> “Transform-HTN is an open-label extension trial allowing participants to continue to receive lorundrostat and for us to obtain ongoing long-term efficacy and safety data.”

Source: [Mineralys Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000056/mlys-20251231.htm)

> “Lorundrostat continues to be evaluated in the ongoing Transform-HTN open-label extension study, which is assessing long-term safety and durability of response.”

Source: [Mineralys Therapeutics press release, ASN Kidney Week 2025 (2025)](https://ir.mineralystx.com/news-events/press-releases/detail/85/data-for-lorundrostat-in-chronic-kidney-disease-and)

<a id="topic-3.1.3.1-3"></a>

#### Role of the trial in the new drug application

> “The Company’s ongoing open-label extension trial, which supported the NDA submission, enables participants to continue to receive lorundrostat and allows the Company to gather additional long-term safety and efficacy data.”

Source: [Mineralys Therapeutics first quarter 2026 results announcement (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/100/mineralys-therapeutics-reports-first-quarter-2026-financial)

<a id="topic-3.1.3.1-4"></a>

#### Scope of the AHA Scientific Sessions 2026 presentation

> “Transform-HTN is an open-label extension trial of lorundrostat for participants enrolled in 1 of 3 parent studies, including Launch-HTN”
> “This presentation focuses on long-term efficacy and safety of lorundrostat for participants in the lorundrostat arms of the Launch-HTN trial who enrolled in the Transform-HTN OLE trial”

Source: [Saxena et al. (2026b)](https://mineralystx.com/wp-content/uploads/2026/11/MV84448B5_AHA-SS2026-TRANSFORM-OLE-study-ORAL-Upload.pdf)

<a id="heading-3.1.3.2"></a>

### 3.1.3.2 Location and Study Date

<a id="topic-3.1.3.2-1"></a>

#### Study dates and status in the ClinicalTrials.gov record

> “Study Start (Actual) 2023-07-14”
> “Primary Completion (Actual) 2025-12-30”
> “Study Completion (Estimated) 2027-05”
> “Active, not recruiting”

Source: [ClinicalTrials.gov NCT05968430](https://clinicaltrials.gov/study/NCT05968430)

<a id="topic-3.1.3.2-2"></a>

#### Registered locations

> “This study has 177 locations”

Source: [ClinicalTrials.gov NCT05968430](https://clinicaltrials.gov/study/NCT05968430)

<a id="topic-3.1.3.2-3"></a>

#### Other study identifiers

> “MLS-101-901”

Source: [ClinicalTrials.gov NCT05968430](https://clinicaltrials.gov/study/NCT05968430)

<a id="topic-3.1.3.2-4"></a>

#### Certification for delayed results submission

> “Certification/Extension First Submitted 2026-07-15”
> “Certification/Extension First Posted 2026-02-17”

Source: [ClinicalTrials.gov NCT05968430](https://clinicaltrials.gov/study/NCT05968430)

<a id="topic-3.1.3.2-5"></a>

#### Presentation of results

> “The results were presented in a late-breaking oral session at the American Heart Association (AHA) Scientific Sessions 2026 in Chicago, IL, on Sunday, November 8, 2026, at 3:35 p.m. CT.”

Source: [Mineralys Therapeutics press release, Transform-HTN results (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/129/mineralys-therapeutics-presents-new-late-breaking-data-from)

> “today announced that new long-term efficacy and safety data from the Company’s ongoing Transform-HTN open-label extension trial of the aldosterone synthase inhibitor lorundrostat will be featured in a late-breaking science presentation at the American Heart Association Scientific Sessions 2026, taking place November 6-9 in Chicago, IL.”

Source: [Mineralys Therapeutics press release, Transform-HTN late-breaker selection (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/116/mineralys-therapeutics-transform-htn-open-label)

<a id="heading-3.1.3.3"></a>

### 3.1.3.3 Study Design

<a id="topic-3.1.3.3-1"></a>

#### Design details in the ClinicalTrials.gov record

| Field | Quoted record |
| --- | --- |
| Primary purpose | “Treatment” |
| Allocation | “Non-Randomized” |
| Interventional model | “Single Group Assignment” |
| Masking | “None (Open Label)” |
| Phase | “Phase 3” |
| Enrollment | “1076” |

Source: [ClinicalTrials.gov NCT05968430](https://clinicaltrials.gov/study/NCT05968430)

<a id="topic-3.1.3.3-2"></a>

#### Open-label treatment period, safety follow-up, and optional continuation

> “This study consists of an open label treatment period of 52 weeks followed by a 2-week safety follow-up period.”
> “A Randomized Treatment Withdrawal (RTW) substudy will be performed in a subset of subjects meeting eligibility criteria.”
> “Subjects who complete the open label treatment period will be invited to consent to an optional continuation period where they may remain on study until marketing authorization or early termination of the trial by the sponsor.”

Source: [ClinicalTrials.gov NCT05968430](https://clinicaltrials.gov/study/NCT05968430)

<a id="topic-3.1.3.3-3"></a>

#### Double-blind randomized treatment withdrawal substudy

> “Eligible subjects participating in the RTW will receive double-blind treatment with matching placebo. Upon completion, subjects will return to open-label treatment”
> “lorundrostat or placebo once daily for 4 weeks starting at week 12, in the double-blind randomized treatment withdrawal substudy”
> “Optional for subjects from the MLS-101-301 parent study only”

Source: [ClinicalTrials.gov NCT05968430](https://clinicaltrials.gov/study/NCT05968430)

<a id="topic-3.1.3.3-4"></a>

#### Timeline relative to the Launch-HTN double-blind period

> “Participants eligible for the RTW sub-study had to have a reduction of ≥5 mmHg in office SBP from Launch-HTN baseline at Week 24.”
> “Analysis conducted at Week 48.”
> “Transform-HTN comprises a 52-week treatment period following the 12-week double-blind period in Launch-HTN (overall treatment duration 64 weeks).”

Source: [Saxena et al. (2026b)](https://mineralystx.com/wp-content/uploads/2026/11/MV84448B5_AHA-SS2026-TRANSFORM-OLE-study-ORAL-Upload.pdf)

> “Of the 808 participants from Launch-HTN's lorundrostat treatment arms, 632 participants were eligible and enrolled in Transform-HTN. These participants received an additional 36 weeks of lorundrostat while continuing their existing antihypertensive medications.”
> “The efficacy analysis (n=504) excluded participants randomized to placebo in a four-week randomized treatment withdrawal sub-study between Weeks 24 and 28.”

Source: [Mineralys Therapeutics press release, Transform-HTN results (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/129/mineralys-therapeutics-presents-new-late-breaking-data-from)

<a id="topic-3.1.3.3-5"></a>

#### Option to enroll at the end of Launch-HTN

> “Upon completion, participants had the option to enroll in an open-label extension trial of lorundrostat or participate in a 2-week safety follow-up.”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

<a id="heading-3.1.3.4"></a>

### 3.1.3.4 Eligibility Criteria

<a id="topic-3.1.3.4-1"></a>

#### Inclusion criteria in the ClinicalTrials.gov record

> “At least 18 years of age at the time of signing the informed consent form (ICF)”
> “Completed the EoT or EoS Visit (as applicable) in a lorundrostat study with the option of transitioning to the OLE study, in accordance with the parent study protocol”
> “Fertile male subjects and female subjects of childbearing potential, and their partners, must agree to use an acceptable method of contraception from study entry to 28 days after the last dose of study drug”
> “Willing and able to comply with the study instructions and attend all scheduled study visits”

Source: [ClinicalTrials.gov NCT05968430](https://clinicaltrials.gov/study/NCT05968430)

<a id="topic-3.1.3.4-2"></a>

#### Exclusion criteria in the ClinicalTrials.gov record

> “Women who are pregnant, plan to become pregnant, or are breast-feeding”
> “Use, or anticipated use during the course of the study, of a prohibited medication as listed in Section 6.7.1 of the protocol”
> “In the opinion of the Investigator, any condition that will preclude participation in the study”

Source: [ClinicalTrials.gov NCT05968430](https://clinicaltrials.gov/study/NCT05968430)

<a id="topic-3.1.3.4-3"></a>

#### Additional criteria for the randomized treatment withdrawal substudy

> “Written informed consent to participate in the RTW substudy signed by the participant, obtained before any RTW study-related assessment is performed”
> “Non-compliance with study medication(s) (defined as taking <75% or >125% of the study drug provided) during the first 12 weeks of MLS-101-901”

Source: [ClinicalTrials.gov NCT05968430](https://clinicaltrials.gov/study/NCT05968430)

> “Participants eligible for the RTW sub-study had to have a reduction of ≥5 mmHg in office SBP from Launch-HTN baseline at Week 24.”

Source: [Saxena et al. (2026b)](https://mineralystx.com/wp-content/uploads/2026/11/MV84448B5_AHA-SS2026-TRANSFORM-OLE-study-ORAL-Upload.pdf)

<a id="topic-3.1.3.4-4"></a>

#### Launch-HTN criteria that defined the presented cohort

> “Office SBP 135-180 mmHg and diastolic BP 65-110 mmHg or isolated office diastolic BP 90-110 mmHg at screening and randomization”
> “2-5 AHTs, including thiazide/thiazide-like diuretic, for ≥1 month pre-screening”
> “eGFR <45 ml/min/1.73 m2”
> “Serum potassium >5.0 mmol/L at screening or >4.8 mmol/L at randomization”
> “Serum sodium <135 mmol/L at screening”
> “Use of epithelial sodium channel inhibitors or MRAs/potassium sparing diuretics”

Source: [Saxena et al. (2026b)](https://mineralystx.com/wp-content/uploads/2026/11/MV84448B5_AHA-SS2026-TRANSFORM-OLE-study-ORAL-Upload.pdf)

<a id="heading-3.1.3.5"></a>

### 3.1.3.5 Treatment

<a id="topic-3.1.3.5-1"></a>

#### Registered arms and interventions

> “lorundrostat once daily for 52 weeks depending on when the subject enrolled”
> “lorundrostat or placebo once daily for 4 weeks starting at week 12, in the double-blind randomized treatment withdrawal substudy”
> “lorundrostat once daily from week 52 or until marketing authorization or early termination of the trial by the sponsor”
> “Tablet, administered orally”

Source: [ClinicalTrials.gov NCT05968430](https://clinicaltrials.gov/study/NCT05968430)

<a id="topic-3.1.3.5-2"></a>

#### Open-label starting dose and background antihypertensive drugs

> “These participants received an additional 36 weeks of lorundrostat while continuing their existing antihypertensive medications. The open-label starting lorundrostat dose was 50 mg once daily, or 25 mg if the previously blinded treatment dose was reduced.”

Source: [Mineralys Therapeutics press release, Transform-HTN results (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/129/mineralys-therapeutics-presents-new-late-breaking-data-from)

> “Participants who had a permanent dose reduction in Launch-HTN started the OLE at a lorundrostat dose of 25 mg QD.”

Source: [Saxena et al. (2026b)](https://mineralystx.com/wp-content/uploads/2026/11/MV84448B5_AHA-SS2026-TRANSFORM-OLE-study-ORAL-Upload.pdf)

<a id="heading-3.1.3.6"></a>

### 3.1.3.6 Study Outcomes

<a id="heading-3.1.3.6.1"></a>

#### 3.1.3.6.1 Rationale for Using Change in Automated Office Systolic Blood Pressure as the Primary Endpoint

<a id="topic-3.1.3.6.1-1"></a>

##### Registered primary outcome measures

> “Change from MLS-101-301 baseline automated office blood pressure (AOBP) systolic blood pressure (SBP) at MLS-101-901 Week 36 in subjects who were enrolled in the lorundrostat arms of MLS-101-301 and were not assigned to the placebo arm of the MLS-101-901 RTW substudy”
> “Change at MLS-101-901 Week 16 (RTW Week 4) from MLS 101-901 Week 12 (RTW substudy baseline) in AOBP SBP in subjects enrolled in RTW”

Source: [ClinicalTrials.gov NCT05968430](https://clinicaltrials.gov/study/NCT05968430)

<a id="topic-3.1.3.6.1-2"></a>

##### Efficacy endpoints in the AHA Scientific Sessions 2026 presentation

> “Primary: Change in office SBP from baseline of Launch-HTN to Week 48”
> “Proportion achieving office SBP <130 mmHg at Week 48”
> “RAAS biomarker changes”
> “Asterisk denotes prespecified efficacy endpoints; other efficacy endpoints were not prespecified.”

Source: [Saxena et al. (2026b)](https://mineralystx.com/wp-content/uploads/2026/11/MV84448B5_AHA-SS2026-TRANSFORM-OLE-study-ORAL-Upload.pdf)

> “Eligible participants were enrolled in the open-label extension study, with a primary endpoint of the change in automated office systolic blood pressure.”

Source: [Mineralys Therapeutics press release, Transform-HTN results (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/129/mineralys-therapeutics-presents-new-late-breaking-data-from)

<a id="topic-3.1.3.6.1-3"></a>

##### Prespecified endpoint: proportion achieving office systolic blood pressure below 130 mmHg

> “Proportion achieving office SBP <130 mmHg at Week 48”

Source: [Saxena et al. (2026b)](https://mineralystx.com/wp-content/uploads/2026/11/MV84448B5_AHA-SS2026-TRANSFORM-OLE-study-ORAL-Upload.pdf)

> “In Transform-HTN, lorundrostat demonstrated sustained blood pressure reductions for nearly a year, with more than half of participants achieving the guideline-recommended systolic blood pressure target of less than 130 mmHg, an important goal for reducing long-term cardiovascular and kidney risks.”

Source: [Mineralys Therapeutics press release, Transform-HTN results (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/129/mineralys-therapeutics-presents-new-late-breaking-data-from)

<a id="topic-3.1.3.6.1-4"></a>

##### Safety endpoints and assessment periods

> “TEAEs, AESIs, and confirmed serum potassium elevation”
> “Assessed in the OLE period (Weeks 12-48)”
> “Change in eGFR and serum potassium and sodium”

Source: [Saxena et al. (2026b)](https://mineralystx.com/wp-content/uploads/2026/11/MV84448B5_AHA-SS2026-TRANSFORM-OLE-study-ORAL-Upload.pdf)

<a id="topic-3.1.3.6.1-5"></a>

##### Placebo-controlled duration in the parent trial and the purpose of the extension

> “First, the efficacy and safety of lorundrostat compared with placebo was evaluated for only 12 weeks. This is consistent with US Food and Drug Administration guidance limiting placebo-controlled studies of antihypertensive medications for this duration. However, eligible participants had the option to continue in an open-label extension trial (NCT05968430), which intends to provide safety and efficacy information relevant to longer-term use of lorundrostat.”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

> “It is no longer ethical to conduct outcome trials that leave one group with untreated hypertension.”

Source: [FDA guidance, hypertension labeling for cardiovascular outcome claims (2011)](https://www.fda.gov/media/134777/download)

<a id="topic-3.1.3.6.1-6"></a>

##### Long-term exposure expected for drugs for chronic non-life-threatening conditions

> “Available information suggests that most ADEs first occur, and are most frequent, within the first few months of drug treatment.”
> “Usually 300 to 600 patients should be adequate.”
> “100 patients exposed for a minimum of one-year is considered to be acceptable to include as part of the safety data base.”
> “The data should come from prospective studies appropriately designed to provide at least one year exposure at dosage levels intended for clinical use.”

Source: [FDA guidance, ICH E1A extent of population exposure (1995)](https://www.fda.gov/media/71180/download)

<a id="topic-3.1.3.6.1-7"></a>

##### Randomized withdrawal as a test of maintained effect in approved add-on products

> “The key secondary endpoint was change in seated office systolic blood pressure for BAXFENDY 2 mg compared with placebo from the start (Week 24) to the end (Week 32) of the randomized withdrawal double-blind period of the trial.”
> “Maintenance of the blood pressure lowering effect of BAXFENDY was demonstrated in the double-blind randomized-withdrawal part of the trial.”

Source: [AstraZeneca BAXFENDY prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/219878Orig1s000lbl.pdf)

> “The persistence of the BP-lowering effect of TRYVIO was demonstrated in part 3 of the trial, in which patients on aprocitentan were re-randomized to placebo or 25 mg aprocitentan following a period during which all patients were treated with 25 mg.”

Source: [Idorsia TRYVIO prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217686s005lbl.pdf)

<a id="topic-3.1.3.6.1-8"></a>

##### Blood pressure reduction as the basis of cardiovascular benefit

> “The similar effects with multiple drug classes with disparate mechanisms of action indicate that it is the decrease in blood pressure, rather than any other property of the drugs, that is largely responsible for these benefits.”
> “Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.”

Source: [FDA guidance, hypertension labeling for cardiovascular outcome claims (2011)](https://www.fda.gov/media/134777/download)

<a id="topic-3.1.3.6.1-9"></a>

##### Unattended automated office measurement in the parent trial

> “After an initial 5-minute rest phase, 5 unattended seated measurements were performed with a 1-minute break between each reading; the last 4 measurements were used to calculate the mean and reduce within-participant variance in measuring BP.”
> “Second, although ambulatory BP measurement is the gold standard for assessment of BP, unattended office BP was used as the primary outcome measure to reflect usual clinical practice.”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

> “Several studies have reported that BP measured with AOBP versus the auscultatory method is closer to awake out-of-office BP levels measured with ambulatory BP monitoring (ABPM).”

Source: [Muntner et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11409525/)

<a id="heading-3.1.3.7"></a>

### 3.1.3.7 Statistical Analysis Description

<a id="heading-3.1.3.7.1"></a>

#### 3.1.3.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.3.7.1-1"></a>

##### Enrollment across all parent studies

> “Enrollment (Actual) 1076”

Source: [ClinicalTrials.gov NCT05968430](https://clinicaltrials.gov/study/NCT05968430)

<a id="topic-3.1.3.7.1-2"></a>

##### Launch-HTN cohort enrolled and analyzed

> “Of 808 patients who received ≥1 dose of lorundrostat in Launch-HTN, 632 (78%) enrolled in the OLE”
> “Efficacy analyses include participants assigned to lorundrostat arms in Launch-HTN who received ≥1 dose of lorundrostat in the OLE and were not assigned to placebo in the RTW (n=504)”
> “Safety analyses include participants assigned to lorundrostat arms in Launch-HTN who received ≥1 dose of lorundrostat in the OLE (n=632)”

Source: [Saxena et al. (2026b)](https://mineralystx.com/wp-content/uploads/2026/11/MV84448B5_AHA-SS2026-TRANSFORM-OLE-study-ORAL-Upload.pdf)

<a id="topic-3.1.3.7.1-3"></a>

##### Planned sample size

No evidence found.

<a id="topic-3.1.3.7.1-4"></a>

##### Number randomized in the randomized treatment withdrawal substudy

No evidence found.

<a id="heading-3.1.3.7.2"></a>

#### 3.1.3.7.2 Description of Analysis Sets

<a id="topic-3.1.3.7.2-1"></a>

##### Efficacy and safety analysis sets

> “The efficacy analysis (n=504) excluded participants randomized to placebo in a four-week randomized treatment withdrawal sub-study between Weeks 24 and 28. The safety analysis (n=632) included participants receiving at least one dose of lorundrostat in the open-label extension.”

Source: [Mineralys Therapeutics press release, Transform-HTN results (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/129/mineralys-therapeutics-presents-new-late-breaking-data-from)

<a id="topic-3.1.3.7.2-2"></a>

##### Population for the registered primary outcome

> “Change from MLS-101-301 baseline automated office blood pressure (AOBP) systolic blood pressure (SBP) at MLS-101-901 Week 36 in subjects who were enrolled in the lorundrostat arms of MLS-101-301 and were not assigned to the placebo arm of the MLS-101-901 RTW substudy”

Source: [ClinicalTrials.gov NCT05968430](https://clinicaltrials.gov/study/NCT05968430)

<a id="topic-3.1.3.7.2-3"></a>

##### Estimand and handling of missing data

> “The LS mean estimate is based on 1,000 imputed datasets using a treatment policy approach.”
> “Data for missing observations at Week 48 were imputed using a shift factor based on change in SBP at Week 12 in the subjects who were randomized to placebo during the double-blind phase.”
> “Data in the figure are observed SBP.”
> “Baseline to Week 12 data for lorundrostat include participants in the 50 mg and 50-100 mg lorundrostat groups of Launch-HTN who entered the OLE.”

Source: [Saxena et al. (2026b)](https://mineralystx.com/wp-content/uploads/2026/11/MV84448B5_AHA-SS2026-TRANSFORM-OLE-study-ORAL-Upload.pdf)

<a id="topic-3.1.3.7.2-4"></a>

##### Population for the duration of treatment and the eGFR equation

> “Analysis includes participants assigned to double-blind treatment in the 4-week RTW.”
> “eGFR based on CKD-EPI 2021 equation.”

Source: [Saxena et al. (2026b)](https://mineralystx.com/wp-content/uploads/2026/11/MV84448B5_AHA-SS2026-TRANSFORM-OLE-study-ORAL-Upload.pdf)

<a id="heading-3.1.3.8"></a>

### 3.1.3.8 Results

<a id="heading-3.1.3.8.1"></a>

#### 3.1.3.8.1 Participant Disposition

<a id="topic-3.1.3.8.1-1"></a>

##### Enrollment, completion, and duration of treatment in the Launch-HTN cohort

> “Of 808 patients who received ≥1 dose of lorundrostat in Launch-HTN, 632 (78%) enrolled in the OLE”
> “549/632 (87%) completed treatment at Week 48”
> “583/632 (92%) completed 48 weeks of follow-up”
> “The median (IQR) duration of treatment was 47.9 weeks (46.7, 48.4)”

Source: [Saxena et al. (2026b)](https://mineralystx.com/wp-content/uploads/2026/11/MV84448B5_AHA-SS2026-TRANSFORM-OLE-study-ORAL-Upload.pdf)

> “Of the 632 participants, 583 (92%) completed 48 weeks of follow-up.”

Source: [Mineralys Therapeutics press release, Transform-HTN results (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/129/mineralys-therapeutics-presents-new-late-breaking-data-from)

<a id="topic-3.1.3.8.1-2"></a>

##### Participants enrolled from Advance-HTN and Explore-CKD

No evidence found.

<a id="heading-3.1.3.8.2"></a>

#### 3.1.3.8.2 Baseline Characteristics

<a id="topic-3.1.3.8.2-1"></a>

##### Baseline characteristics of the Launch-HTN cohort (safety population)

| Characteristic | Lorundrostat (N=632) |
| --- | --- |
| Age, mean ±SD, years | “61.2 ± 10.5” |
| Female, n (%) | “292 (46.2)” |
| Black or African American, n (%) | “155 (24.5)” |
| Hispanic or Latino, n (%) | “248 (39.2)” |
| BMI ≥30 kg/m2, n (%) | “395 (62.5)” |
| eGFR, mean ±SD, mL/min/1.73 m2 | “92.7 ± 17.4” |
| Office SBP, mean ±SD, mmHg | “148.5 ± 11.9” |
| 2 antihypertensive drugs, n (%) | “262 (41.5)” |
| 3 or more antihypertensive drugs, n (%) | “370 (58.5)” |
| Thiazide or thiazide-like diuretic, n (%) | “601 (95.1)” |
| ACE inhibitor or ARB, n (%) | “546 (86.4)” |
| Calcium channel blocker, n (%) | “295 (46.7)” |
| Beta blockers, n (%) | “209 (33.1)” |

Source: [Saxena et al. (2026b)](https://mineralystx.com/wp-content/uploads/2026/11/MV84448B5_AHA-SS2026-TRANSFORM-OLE-study-ORAL-Upload.pdf)

<a id="topic-3.1.3.8.2-2"></a>

##### Baseline office systolic blood pressure of the efficacy population

> “Baseline mean office SBP: 147.9 mmHg”

Source: [Saxena et al. (2026b)](https://mineralystx.com/wp-content/uploads/2026/11/MV84448B5_AHA-SS2026-TRANSFORM-OLE-study-ORAL-Upload.pdf)

<a id="topic-3.1.3.8.2-3"></a>

##### Demographics stated by the sponsor

> “Participants had a mean age of 61 years; 46% were women, 25% were Black or African American and 39% were Hispanic or Latino. Nearly two-thirds (63%) had a BMI of 30 kg/m² or higher; 41% were taking two antihypertensive medications at baseline, while 59% were taking three or more.”

Source: [Mineralys Therapeutics press release, Transform-HTN results (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/129/mineralys-therapeutics-presents-new-late-breaking-data-from)

<a id="heading-3.1.3.8.3"></a>

#### 3.1.3.8.3 Efficacy Results

<a id="topic-3.1.3.8.3-1"></a>

##### Primary endpoint: change in office systolic blood pressure from Launch-HTN baseline to week 48

> “LS mean change from baseline at week 48: -17.8 mmHg (95% CI: -19.6, -16.0); P<0.0001”

Source: [Saxena et al. (2026b)](https://mineralystx.com/wp-content/uploads/2026/11/MV84448B5_AHA-SS2026-TRANSFORM-OLE-study-ORAL-Upload.pdf)

> “In this open-label extension trial, lorundrostat demonstrated a clinically meaningful 17.8 mmHg absolute reduction in AOSBP from the Launch-HTN baseline through 48 weeks (p<0.0001), supporting sustained blood pressure control.”

Source: [Mineralys Therapeutics press release, Transform-HTN results (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/129/mineralys-therapeutics-presents-new-late-breaking-data-from)

<a id="topic-3.1.3.8.3-2"></a>

##### Proportion with office systolic blood pressure below 130 mmHg at week 48

| Group | Participants with office SBP <130 mmHg at week 48 |
| --- | --- |
| Overall | “56.0%” |
| 2 antihypertensive drugs (uncontrolled hypertension) | “55.2%” |
| 3 or more antihypertensive drugs (resistant hypertension) | “56.5%” |

Source: [Saxena et al. (2026b)](https://mineralystx.com/wp-content/uploads/2026/11/MV84448B5_AHA-SS2026-TRANSFORM-OLE-study-ORAL-Upload.pdf)

> “More than half of participants achieved systolic blood pressure below 130 mmHg at the end of the analysis period. Results were similar among participants taking two background antihypertensive medications and those taking three or more.”

Source: [Mineralys Therapeutics press release, Transform-HTN results (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/129/mineralys-therapeutics-presents-new-late-breaking-data-from)

<a id="topic-3.1.3.8.3-3"></a>

##### Renin-angiotensin-aldosterone system biomarkers at week 48 (not prespecified)

| Biomarker | Percent change in geometric mean from baseline at week 48 |
| --- | --- |
| Serum aldosterone | “-54.8%” |
| Plasma renin activity | “+123.9%” |
| Aldosterone-renin ratio | “-79.8%” |

Source: [Saxena et al. (2026b)](https://mineralystx.com/wp-content/uploads/2026/11/MV84448B5_AHA-SS2026-TRANSFORM-OLE-study-ORAL-Upload.pdf)

<a id="topic-3.1.3.8.3-4"></a>

##### Randomized treatment withdrawal substudy: status

> “Randomized treatment withdrawal substudy completed.”

Source: [Mineralys Therapeutics pipeline](https://mineralystx.com/pipeline/)

> “No Results Posted”

Source: [ClinicalTrials.gov NCT05968430](https://clinicaltrials.gov/study/NCT05968430)

<a id="topic-3.1.3.8.3-5"></a>

##### Randomized treatment withdrawal substudy: change in automated office systolic blood pressure from week 12 to week 16

No evidence found.

<a id="topic-3.1.3.8.3-6"></a>

##### Efficacy in participants enrolled from Advance-HTN and Explore-CKD

No evidence found.

<a id="heading-3.1.3.8.4"></a>

#### 3.1.3.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.3.8.5"></a>

#### 3.1.3.8.5 Safety Results

<a id="topic-3.1.3.8.5-1"></a>

##### Adverse events during the 36-week open-label period

| Participants, n (%) | Lorundrostat (N=632) |
| --- | --- |
| Any treatment-emergent adverse event | “413 (65.3)” |
| Moderate intensity | “141 (22.3)” |
| Severe intensity | “20 (3.2)” |
| Treatment-emergent adverse event leading to study drug withdrawal | “37 (5.9)” |
| Hyperkalemia leading to study drug withdrawal | “10 (1.6)” |
| Any serious adverse event | “27 (4.3)” |
| Death | “0” |
| Treatment-related serious treatment-emergent adverse event (investigator determined) | “2 (0.3)” |
| Hyperkalemia requiring trial drug modification (adverse event of special interest) | “32 (5.1)” |
| Hyponatremia requiring trial drug modification (adverse event of special interest) | “28 (4.4)” |
| Hypotension with symptoms (adverse event of special interest) | “13 (2.1)” |
| Serum potassium >6.0 mmol/L, confirmed per protocol repeat testing | “16 (2.5)” |

Source: [Saxena et al. (2026b)](https://mineralystx.com/wp-content/uploads/2026/11/MV84448B5_AHA-SS2026-TRANSFORM-OLE-study-ORAL-Upload.pdf)

<a id="topic-3.1.3.8.5-2"></a>

##### Definition of adverse events of special interest requiring drug modification

> “Trial drug had to be modified due to the adverse event (dose reduction, interruption, or discontinuation).”

Source: [Saxena et al. (2026b)](https://mineralystx.com/wp-content/uploads/2026/11/MV84448B5_AHA-SS2026-TRANSFORM-OLE-study-ORAL-Upload.pdf)

<a id="topic-3.1.3.8.5-3"></a>

##### Serious adverse events, discontinuations, and hyperkalemia stated by the sponsor

> “Serious adverse events occurred in 27 participants (4.3%). Investigators considered two of these (0.3%) treatment-related. Thirty-seven participants (5.9%) discontinued the trial drug because of an adverse event, including 10 (1.6%) for hyperkalemia.”
> “Hyperkalemia requiring a trial drug modification (dose reduction, interruption, or discontinuation) occurred in 32 participants (5.1%).”

Source: [Mineralys Therapeutics press release, Transform-HTN results (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/129/mineralys-therapeutics-presents-new-late-breaking-data-from)

<a id="topic-3.1.3.8.5-4"></a>

##### Kidney function and serum potassium over time

> “An early drop in eGFR was observed, as expected, after which eGFR remained stable within each study”
> “Creatinine: enzymatic assay”
> “Creatinine: Jaffe assay”

Source: [Saxena et al. (2026b)](https://mineralystx.com/wp-content/uploads/2026/11/MV84448B5_AHA-SS2026-TRANSFORM-OLE-study-ORAL-Upload.pdf)

> “Consistent with lorundrostat’s mechanism of action, serum potassium increased and eGFR decreased early in treatment; both remained stable through the open-label period to Week 48.”

Source: [Mineralys Therapeutics press release, Transform-HTN results (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/129/mineralys-therapeutics-presents-new-late-breaking-data-from)

<a id="topic-3.1.3.8.5-5"></a>

##### Overall tolerability conclusion of the presenters

> “Treatment with long-term lorundrostat was well tolerated, with no new clinically relevant safety findings”

Source: [Saxena et al. (2026b)](https://mineralystx.com/wp-content/uploads/2026/11/MV84448B5_AHA-SS2026-TRANSFORM-OLE-study-ORAL-Upload.pdf)

> “Lorundrostat was well tolerated during the 36-week open-label extension, with no new clinically relevant safety findings compared with Launch-HTN.”

Source: [Mineralys Therapeutics press release, Transform-HTN results (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/129/mineralys-therapeutics-presents-new-late-breaking-data-from)

<a id="heading-3.1.3.9"></a>

### 3.1.3.9 Study Limitations

<a id="topic-3.1.3.9-1"></a>

#### Summary

Transform-HTN is a phase 3, single-group, open-label extension registered with 1,076 participants from three parent studies (Launch-HTN, Advance-HTN, and Explore-CKD). The only results available as of November 2026 are for the Launch-HTN cohort, presented as congress slides and a company press release on November 8, 2026; no peer-reviewed publication and no posted registry results were located, and the record lists a certification or extension request for results submission first submitted on July 15, 2026. Of 808 participants who received lorundrostat in Launch-HTN, 632 (78%) enrolled, so the cohort is limited to participants who completed the parent trial and chose to continue, which may favor participants who tolerated and responded to treatment. The primary endpoint is a within-group change from the Launch-HTN baseline, which includes the 12-week double-blind period; after the 12-week double-blind period there was no concurrent control group except during the 4-week withdrawal substudy, and in Launch-HTN the placebo group's automated office systolic blood pressure fell by 7.9 mm Hg at week 6, so the 17.8 mmHg change at week 48 cannot be attributed entirely to lorundrostat. The efficacy analysis (504 participants) excluded participants randomized to placebo in the withdrawal substudy, whereas the safety analysis included all 632; missing week 48 values were imputed with a shift factor based on the parent trial's placebo group. The randomized treatment withdrawal substudy, the only randomized comparison in the trial, is a registered primary outcome (change in automated office systolic blood pressure from extension week 12 to week 16) and is listed as completed, but neither its sample size nor its results were located in any public document. Only the office systolic blood pressure change and the proportion below 130 mmHg were prespecified; the biomarker results were not. Serum creatinine was measured by an enzymatic assay in Launch-HTN and a Jaffe assay in the extension, which limits comparison of eGFR across the two periods. No quality-of-life or patient-reported outcome was reported, and no results were located for participants who entered from Advance-HTN or Explore-CKD.

Source: [ClinicalTrials.gov NCT05968430](https://clinicaltrials.gov/study/NCT05968430); [Saxena et al. (2026b)](https://mineralystx.com/wp-content/uploads/2026/11/MV84448B5_AHA-SS2026-TRANSFORM-OLE-study-ORAL-Upload.pdf); [Mineralys Therapeutics press release, Transform-HTN results (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/129/mineralys-therapeutics-presents-new-late-breaking-data-from); [Mineralys Therapeutics pipeline](https://mineralystx.com/pipeline/); [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

<a id="topic-3.1.3.9-2"></a>

#### Interpretive limits of uncontrolled long-term studies

> “A study that has no concurrent control group makes it more difficult to assess the causality relationship between adverse events observed and the test drug.”

Source: [FDA guidance, ICH E1A extent of population exposure (1995)](https://www.fda.gov/media/71180/download)

## Related pages
- [Lorundrostat (MLS-101): Hypertension, in combination with other antihypertensive drugs](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Terms and abbreviations](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/terms-and-abbreviations.md)
- [Lorundrostat (MLS-101): Hypertension, in combination with other antihypertensive drugs](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/executive-summary.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Product information and disease description](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Clinical evidence](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Economic information and modeling report](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: References](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/references) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/references.md)
